Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases 125,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 125,000 shares of the company’s stock in a transaction on Tuesday, April 8th. The shares were purchased at an average price of $1.48 per share, for a total transaction of $185,000.00. Following the purchase, the chief executive officer now owns 213,876,448 shares in the company, valued at approximately $316,537,143.04. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Tuesday, April 1st, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.65 per share, for a total transaction of $165,000.00.
• On Friday, March 28th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was bought at an average price of $1.70 per share, for a total transaction of $255,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost purchased 200,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost purchased 67,434 shares of OPKO Health stock. The stock was acquired at an average cost of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost purchased 47,537 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.48 per share, with a total value of $740,000.00.

OPKO Health Trading Up 2.1 %

NASDAQ:OPK opened at $1.49 on Thursday. The stock has a fifty day moving average price of $1.69 and a 200 day moving average price of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12-month low of $1.15 and a 12-month high of $2.04. The firm has a market cap of $1.00 billion, a PE ratio of -7.84 and a beta of 1.78.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. Sell-side analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently added to or reduced their stakes in OPK. Millennium Management LLC boosted its holdings in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in OPKO Health by 143.6% in the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after purchasing an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd purchased a new stake in OPKO Health in the 4th quarter valued at approximately $2,082,000. Norges Bank purchased a new stake in OPKO Health in the 4th quarter valued at approximately $1,657,000. Finally, Two Sigma Investments LP boosted its holdings in OPKO Health by 136.1% in the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after purchasing an additional 949,671 shares in the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Ratings Changes

OPK has been the subject of several recent research reports. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Monday.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.